Results 161 to 170 of about 236,085 (267)

Targeted Lysosomal Degradation of Extracellular and Membrane Proteins: From Receptor Hijacking to Programmable Endolysosomal Routing

Advanced Science, EarlyView.
Targeted chimeric degraders engage extracellular or membrane proteins and endocytosable cell‐surface receptors, forming ternary complexes that induce receptor‐mediated internalization. Following endocytosis, post‐endocytic sorting—not internalization alone—determines target fate.
Ke Liu, Xiyan Wang, Xiaozhen Liu, Chaoqi He, Da Qian, Xuli Meng, Liquan Zhu   +6 more
wiley   +1 more source

A clinicopathological study of borderline ovarian tumors: insights from a tertiary care center in Saudi Arabia. [PDF]

BMC Womens Health
Baradwan S, Latifah HM, Hafedh B, Al-Maghrabi H, Almarzugi R, Aljabri W, Edrees A.   +6 more
europepmc   +1 more source

SOX30 Facilitates Triple‐Negative Breast Cancer Metastasis via TNFR2–NF‐κB Signaling and Tumor Microenvironment Remodeling

Advanced Science, EarlyView.
SOX30 drives triple‐negative breast cancer (TNBC) metastasis through a dual mechanism: direct activation of the TNFR2/NF‐κB signaling cascade and subsequent CCL20‐mediated recruitment of tumor‐associated macrophages (TAMs) into the tumor microenvironment.
Pingping Gao, Na Sun, Ning Yang, Tingting Zhao, Rui Fu, Zhenyu Wu, Yuqin Zhou, Xuanni Tan, Yi Zhang, Fei Han, Xiaowei Qi   +10 more
wiley   +1 more source

Fertility preservation by ex vivo oocyte retrieval in a 17-year-old with bilateral borderline ovarian tumors: a case report. [PDF]

JBRA Assist Reprod
Furtado RG, Furtado F, Ribeiro R, Hauer IR, Sonaglio L, Furtado F, Wandresen G, Nisihara R.   +7 more
europepmc   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

Advanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao, Yuechen Han, Jie Li, Peng Luo, Lin Qi, Zhiwei Xia, Xiaosong Li, Quan Cheng, Chenshen Huang, Wantao Wu, Hao Zhang   +10 more
wiley   +1 more source

"Is the incidence of non-epithelial ovarian tumors on the rise? insights from a Tunisian tertiary center". [PDF]

Front Oncol
Abdelmoula G, Garci M, Abdessayed N, Makni M, Abdeljabbar A, Babay W, Ben Saada N, Mathlouthi N, Belghith C, Slimani O.   +9 more
europepmc   +1 more source

SAV1 in Cooperation With FKBP52 Participates in Implantation

Advanced Science, EarlyView.
The MST‐SAV1 complex modulates FKBP52 phosphorylation to fine‐tune PR activity, ensuring timely uterine transition to receptivity under estrogen signaling for implantation. Stromal SAV1 scaffolds MST1/2‐mediated FKBP52 phosphorylation via noncanonical Hippo to promote PR activity.
Yuhan Shao, Yafang Lu, Zhaoyu Jia, Junxiang Ren, Ziyi Ge, Xinyu Liu, Hui Zhao, Zi‐Jiang Chen, Junhao Yan, Wei Wang, Jia Yuan   +10 more
wiley   +1 more source

Trends in the management and prognosis of mucinous borderline ovarian tumors: analysis of 12,766 cases from the JSOG Gynecologic Tumor Registry (2004-2018). [PDF]

Int J Clin Oncol
Tokunaga H, Shibuya Y, Yamagami W, Takahashi F, Yamamoto E, Yokoyama Y, Yoshino K, Kawana K, Nagase S.   +8 more
europepmc   +1 more source

Plant Metabolites Screening Identifies 7‐epi‐10‐Deacetyltaxol Inhibiting Cell Division by Interfering With the Cell Cycle and Microtubule Organization

Advanced Science, EarlyView.
In this study, an efficient screening system is developed for plant metabolites to find a compound, 7‐epi‐10‐deacetyltaxol, inhibits tissue elongation. It suppresses plant growth through brassinosteroid and microtubule pathways. It is later applied to animal cells and human tumor organoids, resulting in similar cell division suppression. These findings
Yan‐Jie Zhang, Yu‐Xuan Bai, Geng G. Tian, Bin Zhang, Ding‐Yi Lu, Qing‐Ping Yao, Wen‐Hao Tian, Xiao‐Na Wei, Jing‐Ting Yang, Ze‐Yu Xiong, Yi Lu, Yu‐Tong Jiang, Chun‐Hui Cai, Yu‐Ming Lu, Xian‐Qing Jia, Li‐Li Jing, Bao‐Jun Yang, Ying‐Xin Qi, Xin‐Xin Han, Ji Wu, Wen‐Hui Lin   +20 more
wiley   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source